Revolution Medicines Inc. (RVMD)
RVMD trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1628171/000119312526071563/0001193125-26-071563-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RVMD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001628171 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$1.1B |
| Operating income | -$1.2B |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $383.7M |
| Total assets | $2.4B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $615.9M cash; operating cash flow -$357.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 216,292,323 (2026-10-30); 193,319,805 a year earlier; 109,564,695 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the market | Latest 2026-04-15 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Jose, California, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $155.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $197.6M | -$407.5M | -$415.6M | $615.9M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | Not filed | -$644.4M | -$387.3M | $815.4M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2026 2026-03-31 | Not filed | -$453.8M | -$354.2M | $440.9M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2025 2025-12-31 | $0 | -$364.9M | -$274.2M | $383.7M | No debt tags | $0 | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $0 | -$305.2M | -$207.3M | $217.4M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | Not filed | -$247.8M | -$221.8M | $402.4M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2025 2025-03-31 | Not filed | -$213.4M | -$194.4M | $333.6M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2024 2024-12-31 | $0 | -$194.6M | -$138.3M | $543.1M | No debt tags | $0 | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-15 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 870 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.4% |
| 1 month | -8.6% |
| 3 months | -14.7% |
| Year to date | +116.3% |
| 1 year | +167.6% |
| From 52-week high | -22.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| RVMDW | Revolution Medicines Inc. Warrant | $7.12 |
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BIIB | Biogen Inc. | $251.65 | -0.69% | $37.2B |
| ARGX | argenx SE | $950.95 | -0.95% | $59.0B |
| BNTX | BioNTech SE American Depositary Share | $85.26 | -0.40% | $21.4B |
| NBIX | Neurocrine Biosciences Inc. | $165.31 | -1.25% | $16.7B |
| EXEL | Exelixis Inc. | $67.10 | -2.75% | $16.4B |
| MRNA | Moderna Inc. | $215.27 | -3.63% | $87.1B |
| TECH | Bio-Techne Corp | $72.79 | -0.01% | $11.4B |
| HALO | Halozyme Therapeutics Inc. | $96.50 | -3.76% | $11.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier